Disclosed are oral care compositions of novel phosphono-phosphate and anionic group containing polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver anionic character to surfaces such as calcium hydroxyapatite for use in oral care applications.

The present disclosure relates to a compound, an organic electroluminescent device, and a display device. The compound has a structure of formula (I) ##STR00001## X is selected from a C atom, a Si atom, a B atom, or a P atom; Y.sub.1 to Y.sub.4 are each independently selected from a C atom or an N atom; A and B are each independently selected from any one or more of a substituted or unsubstituted C6-C40 aryl group and a substituted or unsubstituted C4-C40 heteroaryl group; R.sub.1 is selected from carbonyl, C1-C9 alkyl, a substituted or unsubstituted C6-C18 aryl group, and a substituted or unsubstituted C4-C30 heteroaryl group; and R.sub.2 and R.sub.3 are each independently selected from any one of a C1-C9 alkyl group, a substituted or unsubstituted C6-C18 aryl group, and a substituted or unsubstituted C4-C30 heteroaryl group, and n is selected from 0 or 1.

Provided herein are compounds useful for the treatment of cancer.

Provided herein are compounds useful for the treatment of cancer.

The present invention provides compounds of Formula I′: ##STR00001##
wherein , W, X, Y, Z, Z.sub.1, Z.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

The present invention provides compounds of Formula I′: ##STR00001##
wherein , W, X, Y, Z, Z.sub.1, Z.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

The present invention relates to chiral phosphoramidimidates, their salts and metal complexes as well as derivatives thereof and their use as catalysts.

The present invention relates to chiral phosphoramidimidates, their salts and metal complexes as well as derivatives thereof and their use as catalysts.

Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1

##STR00001##

Pharmaceutical compositions of compound 1 are also disclosed.

Disclosed are novel phosphono-phosphate compounds, monomers, and polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver actives to surfaces such as calcium hydroxyapatite.